Improving awareness of several combination therapies for acute myeloid leukemia among oncology and hematology team members in Colorado, USA
Hematol., Transfus. Cell Ther. (Impr.)
; 44(3): 358-364, July-Sept. 2022. tab, graf
Artigo
em Inglês
| LILACS
| ID: biblio-1405011
Biblioteca responsável:
BR408.1
Localização: BR408.1
ABSTRACT
ABSTRACT Introduction: Although several combination therapies for acute myeloid leukemia (AML) have emerged recently, there has been a lack of published surveys and educational projects focused on these important treatment options. We aimed to improve the oncology team members' knowledge and awareness of several FDA approved combination therapies for AML, including glasdegib (DAURISMO®), venetoclax (VENCLEXTA®), GO (MYOLOTARG®),CPX-351 (VYXEOS®), and midostaurin (RYDAPT®). Additionally, we aimed to examine these teams' perspectives, views, and attitudes towards these topics and finally identify barriers to the implementationof such therapies in clinical practice. Method: Initially, we developed booklets and then distributed them to each participating oncology and hematology office. Subsequently, all participating oncology and hematology team members were asked to complete an anonymous online survey to test their knowledge of and attitudes toward the subjects. Main results: There was a total of 52 survey respondents. The correct answer regarding various combination therapies for AML was identified by nearly 70% or more of survey takers. The level of awareness of project subjects significantly improved after reading our printing materials. Many survey respondents were motivated to learn more about combination therapies for AML as well as discuss these topics with others. Conclusions: Our booklets effectively improved understanding and awareness of combination therapies for AML. Future studies should explore awareness, knowledge, and perception of other new and emerging combination therapies for AML amongoncology and hematology team members in other areas.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Leucemia Mieloide Aguda
Limite:
Adulto
/
Idoso
/
Idoso, 80 anos ou mais
/
Humanos
Idioma:
Inglês
Revista:
Hematol., Transfus. Cell Ther. (Impr.)
Assunto da revista:
Hematologia
/
TransfusÆo de Sangue
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
Brasil
/
Espanha
/
Estados Unidos
Instituição/País de afiliação:
Aging and Trauma (CMDAT) Research Foundation/US
/
The University of Texas M.D. Anderson Cancer Center/US
/
Universidade Federal do Rio de Janeiro (UFRJ)/BR
/
University of Barcelona/ES